VANCOUVER, BC, May 11, 2021 /PRNewswire/ — Bold Therapeutics, a clinical-stage biopharmaceutical company, is announcing that the U.S. Food & Drug Administration (FDA) has granted BOLD-100 an Orphan Drug Designation (ODD)… Read More
Vancouver, BC – May 6, 2021 – InMed Pharmaceuticals Inc. (“InMed” or the “Company”) (NASDAQ:INM; TSX:IN), a clinical-stage company developing pharmaceutical-based drug candidates and leading the way in the clinical… Read More
Vancouver, British Columbia–(Newsfile Corp. – May 11, 2021) – Amphotericin B Technologies, Inc (“Amp B Tech” or the “Company”), a wholly-owned subsidiary of iCo Therapeutics, Inc. (TSXV: ICO) (“iCo”), announced… Read More
THOUSAND OAKS, Calif., May 10, 2021 —Amgen (NASDAQ: AMGN) today announced its partner AstraZeneca (NASDAQ: AZN) submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA)… Read More
Overview of the Program With the establishment of Lumira Ventures Fund IV, the largest life sciences focused venture fund ever raised in Canada, we are launching our Lumira Ventures Venture… Read More
